| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
58,625,000 |
| Market
Cap: |
1.76(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.72 - $37.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
98,505 |
119,208 |
124,343 |
450,780 |
| Total Sell Value |
$3,345,846 |
$3,929,526 |
$4,091,741 |
$15,155,681 |
| Total People Sold |
1 |
5 |
5 |
6 |
| Total Sell Transactions |
6 |
10 |
11 |
37 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hudson Frederick M. |
Director |
– • – |
2023-11-15 |
4 |
S |
$28.50 |
$259,151 |
D/D |
(9,093) |
33,231 |
|
-18% |
|
| Hudson Frederick M. |
Director |
– • – |
2023-11-15 |
4 |
OE |
$9.24 |
$68,903 |
D/D |
7,457 |
42,324 |
|
- |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2023-11-14 |
4 |
S |
$28.13 |
$31,224 |
D/D |
(1,110) |
5,681 |
|
-16% |
|
| Mottola Frank |
SVP, Quality, GMP, Ops, IT |
• – – |
2023-11-14 |
4 |
OE |
$9.24 |
$18,480 |
D/D |
2,000 |
6,791 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-10-13 |
4 |
D |
$26.91 |
$51,425 |
D/D |
(1,911) |
5,089 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-10-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
7,000 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2023-09-07 |
4 |
D |
$32.10 |
$37,942 |
D/D |
(1,182) |
7,165 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2023-09-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
8,347 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-09-07 |
4 |
D |
$32.10 |
$539,408 |
D/D |
(16,804) |
867,463 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-09-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
884,267 |
|
- |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2023-08-25 |
4 |
S |
$31.59 |
$162,215 |
D/D |
(5,135) |
85,249 |
|
12% |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
750 |
5,497 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-05-11 |
4 |
D |
$36.47 |
$25,857 |
D/D |
(709) |
2,650 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
3,359 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-05-11 |
4 |
D |
$36.47 |
$547,232 |
D/D |
(15,005) |
849,267 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,250 |
864,272 |
|
- |
|
| Bhatt Padmanabh P. |
Sr. VP of IP, CSO |
• – – |
2023-04-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
4,747 |
|
- |
|
| Khattar Jack A. |
President, CEO |
• • – |
2023-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
833,022 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-03-14 |
4 |
D |
$38.65 |
$30,495 |
D/D |
(789) |
2,052 |
|
- |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
2,841 |
|
- |
|
| Mottola Frank |
Sr VP, Quality, GMP Oper. & IT |
• – – |
2023-03-14 |
4 |
S |
$35.99 |
$172,023 |
D/D |
(4,780) |
4,737 |
|
17% |
|
| Dec Timothy C |
Senior Vice-President & CFO |
• – – |
2023-02-22 |
4/A |
D |
$38.57 |
$7,444 |
D/D |
(193) |
1,148 |
|
- |
|
| Martin Tami Tillotson |
Sr. V.P., Regulatory Affairs |
• – – |
2023-02-22 |
4/A |
D |
$38.57 |
$11,147 |
D/D |
(289) |
90,034 |
|
- |
|
| Mottola Frank |
Sr VP, Quality, GMP Oper. & IT |
• – – |
2023-02-22 |
4/A |
D |
$38.57 |
$11,147 |
D/D |
(289) |
9,228 |
|
- |
|
| Rubin Jonathan |
SVP, Chief Medical Officer |
• – – |
2023-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
750 |
2,497 |
|
- |
|
345 Records found
|
|
Page 3 of 14 |
|
|
0.76 (2.59%) 
